Related Experiment Video
Updated: Jan 26, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Tyrosine Kinase Inhibitor Gold Nanoconjugates for the Treatment of Non-Small Cell Lung Cancer
Abstract:
Gold nanoparticles (AuNPs) have emerged as promising drug delivery candidates that can be leveraged for cancer therapy. Lung cancer (LC) is a heterogeneous disease that imposes a significant burden on society, with an unmet need for new therapies. Chemotherapeutic drugs such as afatinib (Afb), which is clinically approved for the treatment of epidermal growth factor receptor positive LC, is hydrophobic and has low bioavailability leading to spread around the body, causing severe side effects. Herein, we present a novel afatinib-AuNP formulation termed Afb-AuNPs, with the aim of improving drug efficacy and biocompatibility. This was achieved by synthesis of an alkyne-bearing Afb derivative and reaction with azide-functionalized lipoic acid using copper-catalyzed click chemistry, then conjugation to AuNPs via alkylthiol-gold bond formation. The Afb-AuNPs were found to possess up to 3.7-fold increased potency when administered to LC cells in vitro and were capable of significantly inhibiting cancer cell proliferation, as assessed by MTT assay and electric cell-substrate impedance sensing, respectively. Furthermore, when exposed to Afb-AuNPs, human alveolar epithelial type I-like cells, a model of the healthy lung epithelium, maintained viability and were found to release less proinflammatory cytokines when compared to free drug, demonstrating the biocompatibility of our formulation. This study provides a new platform for the development of nontraditional AuNP conjugates which can be applied to other molecules of therapeutic or diagnostic utility, with potential to be combined with photothermal therapy in other cancers.
Insights
This study developed novel gold nanoparticle (AuNP) drug delivery systems for lung cancer (LC) therapy. The new afatinib-AuNP formulation enhances drug potency and reduces side effects, offering a promising new treatment approach.
Area of Science:
- Nanotechnology
- Biomedical Engineering
- Materials Science
Background:
- Lung cancer (LC) presents a significant therapeutic challenge due to its heterogeneity and the limitations of existing treatments.
- Hydrophobic chemotherapeutics like afatinib (Afb) exhibit poor bioavailability and severe side effects, necessitating improved drug delivery strategies.
- Gold nanoparticles (AuNPs) offer potential as advanced drug carriers for targeted cancer therapy.
Purpose of the Study:
- To develop a novel afatinib-gold nanoparticle (Afb-AuNP) formulation for enhanced lung cancer treatment.
- To improve the efficacy and biocompatibility of afatinib through nanoparticle-based drug delivery.
- To establish a versatile platform for creating new AuNP conjugates for therapeutic and diagnostic applications.
Main Methods:
- Synthesis of an alkyne-bearing afatinib derivative.
- Copper-catalyzed click chemistry to conjugate afatinib to azide-functionalized lipoic acid.
- Formation of Afb-AuNPs via alkylthiol-gold bond linkage.
- In vitro assessment of Afb-AuNP potency and cancer cell proliferation inhibition using MTT assay and electric cell-substrate impedance sensing.
- Evaluation of Afb-AuNP biocompatibility using human alveolar epithelial cells.
Main Results:
- The Afb-AuNP formulation demonstrated up to 3.7-fold increased potency against lung cancer cells in vitro.
- Afb-AuNPs significantly inhibited cancer cell proliferation.
- Healthy lung epithelial cells maintained viability and exhibited reduced proinflammatory cytokine release upon exposure to Afb-AuNPs compared to free afatinib, indicating improved biocompatibility.
- The study established a novel platform for developing AuNP conjugates.
Conclusions:
- The novel Afb-AuNP formulation represents a significant advancement in lung cancer therapy, enhancing drug efficacy and biocompatibility.
- This nanoparticle-based approach offers a promising strategy to overcome the limitations of conventional chemotherapy.
- The developed platform can be extended to other therapeutic or diagnostic molecules and potentially combined with photothermal therapy for broader cancer treatment applications.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:26Receptor Tyrosine Kinases
02:54Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
02:54Protein Kinases and Phosphatases
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
02:56Treatment Resistant Cancers